Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology
- PMID: 31550176
- PMCID: PMC6874004
- DOI: 10.1200/CCI.19.00089
Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology
Abstract
Genomic testing has become a part of routine oncology care and plays critical roles in diagnosis, prognostic assessment, and treatment selection. Thus, in parallel, the variety of genomic testing providers and sequencing platforms has grown exponentially. Selection of the best-fit panel for each case can be daunting, with many factors to consider. Among them is whether alteration interpretation and therapy/clinical trial matching are included and/or sufficient. In this article, we review some common commercially available sequencing platforms for the genes and types of alterations tested, samples needed, and reporting content provided. We review publicly available resources for a do-it-yourself approach to alteration interpretation when it is not provided or when supplemental research is needed, along with resources to identify genomically matched treatment options that are approved and/or investigational. However, with both commercially provided interpretation and publicly available resources, there are still caveats and limitations that can stem from insufficient or ambiguous nomenclature as well as from the presentation of information. Use cases in which clinical decision making was affected are discussed. After treatment options are identified, it is important to assess the level of evidence for use within the patient's tumor type and molecular profile. However, numerous level-of-evidence scales have been published in recent years, so we provide a publicly available tool to facilitate interoperability. The level of evidence, along with other factors, such as allelic frequency and copy number, can be used to prioritize treatment options when multiple are identified.
Conflict of interest statement
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to
Jia Zeng
Dong Yang
Thuy Vu
Funda Meric-Bernstam
No other potential conflicts of interest were reported.
Figures
Similar articles
-
Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice.JCO Precis Oncol. 2021 May 20;5:PO.20.00513. doi: 10.1200/PO.20.00513. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34095711 Free PMC article. Review.
-
Precision Oncology Decision Support: Current Approaches and Strategies for the Future.Clin Cancer Res. 2018 Jun 15;24(12):2719-2731. doi: 10.1158/1078-0432.CCR-17-2494. Epub 2018 Feb 2. Clin Cancer Res. 2018. PMID: 29420224 Free PMC article. Review.
-
Physician interpretation of genomic test results and treatment selection.Cancer. 2018 Mar 1;124(5):966-972. doi: 10.1002/cncr.31112. Epub 2017 Nov 22. Cancer. 2018. PMID: 29165790 Free PMC article.
-
Enabling Precision Oncology Through Precision Diagnostics.Annu Rev Pathol. 2020 Jan 24;15:97-121. doi: 10.1146/annurev-pathmechdis-012418-012735. Annu Rev Pathol. 2020. PMID: 31977297 Review.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
Cited by
-
Impact of Precision Medicine on Clinical Outcomes: A Single-Institution Retrospective Study.Front Oncol. 2021 Aug 31;11:659113. doi: 10.3389/fonc.2021.659113. eCollection 2021. Front Oncol. 2021. PMID: 34540658 Free PMC article.
-
Sex-dependent Prognosis of Patients with Advanced Soft Tissue Sarcoma.Clin Cancer Res. 2024 Jan 17;30(2):413-419. doi: 10.1158/1078-0432.CCR-23-1990. Clin Cancer Res. 2024. PMID: 37831066 Free PMC article.
-
Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network.Oncologist. 2022 Nov 3;27(11):930-939. doi: 10.1093/oncolo/oyac134. Oncologist. 2022. PMID: 35852437 Free PMC article.
-
Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice.JCO Precis Oncol. 2021 May 20;5:PO.20.00513. doi: 10.1200/PO.20.00513. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34095711 Free PMC article. Review.
-
How to read a next-generation sequencing report-what oncologists need to know.ESMO Open. 2022 Oct;7(5):100570. doi: 10.1016/j.esmoop.2022.100570. Epub 2022 Sep 29. ESMO Open. 2022. PMID: 36183443 Free PMC article. Review.
References
-
- O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13:417–430. - PubMed
-
- Freedman AN, Klabunde CN, Wiant K, et al. Use of next-generation sequencing tests to guide cancer treatment: Results from a nationally representative survey of oncologists in the United States. JCO Precis Oncol. 10.1200/PO.18.00169. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
